Johnson & Johnson’s (JNJ) products are part of our daily living. Tylenol, Aveeno, Band-Aid and, of course, Johnson’s Baby Powder are well known brands. But did you know that Johnson & Johnson is the leading company in the medical devices industry and the 5th largest pharmaceutical company?
Fast Track results: Johnson & Johnson’s stock failed 3 categories, and is an idea worthwhile thoroughly researching.
Key Points:
Generated $12.3 billion of free cash flow last year.
- Generated $12.3 billion of free cash flow last year.
- Ended 2007 with $9.3 billion of cash and marketable securities on the balance sheet.
- Long-term debt as a percentage of total capital is a low 14%.
- Warren Buffett’s Berkshire Hathaway is a major shareholder with 61.8 million shares.
The Company Stock Risk Profile Fast Track is a research tool for quickly and easily screening stocks for potential ideas. Fast Track is comprised of 10 key categories incorporating fundamentals, valuation and how management and the Street feel about the stock. I like to see a stock fail no more than 3 categories before putting the stock through the complete 50-category Company Stock Risk Profile research process. Most important, whatever screening tool you choose to use, always thoroughly research the stocks that pass your screen before buying.
